Myasthenia gravis: Past, present and future

Hiroyuki Murai

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Myasthenia gravis (MG) was first described in 17th century. It was after 1960s, when it became clear that MG was an autoimmune disease targeting AChR. Recently, anti-MuSK and anti-Lrp4 antibodies were found as novel antibodies in MG. In 1980s, in addition to cholinesterase inhibitors, high-dose corticosteroid treatment was introduced. This dramatically reduced the mortality rate of MG, but now we recognized that side effects of steroid have influenced patients significantly, and that high dose of steroid correlate with poor QOL. Since we have more means to treat MG at present, and also in the future, we should shift to the strategy in which steroid dose is kept low.

Original languageEnglish
Pages (from-to)947-949
Number of pages3
JournalClinical Neurology
Volume54
Issue number12
DOIs
Publication statusPublished - Jan 1 2014

Fingerprint

Myasthenia Gravis
Steroids
Cholinesterase Inhibitors
Autoimmune Diseases
Anti-Idiotypic Antibodies
Adrenal Cortex Hormones
Mortality
Antibodies

All Science Journal Classification (ASJC) codes

  • Clinical Neurology

Cite this

Myasthenia gravis : Past, present and future. / Murai, Hiroyuki.

In: Clinical Neurology, Vol. 54, No. 12, 01.01.2014, p. 947-949.

Research output: Contribution to journalArticle

Murai, Hiroyuki. / Myasthenia gravis : Past, present and future. In: Clinical Neurology. 2014 ; Vol. 54, No. 12. pp. 947-949.
@article{7cf34f906ff74693a247299c9c0a3434,
title = "Myasthenia gravis: Past, present and future",
abstract = "Myasthenia gravis (MG) was first described in 17th century. It was after 1960s, when it became clear that MG was an autoimmune disease targeting AChR. Recently, anti-MuSK and anti-Lrp4 antibodies were found as novel antibodies in MG. In 1980s, in addition to cholinesterase inhibitors, high-dose corticosteroid treatment was introduced. This dramatically reduced the mortality rate of MG, but now we recognized that side effects of steroid have influenced patients significantly, and that high dose of steroid correlate with poor QOL. Since we have more means to treat MG at present, and also in the future, we should shift to the strategy in which steroid dose is kept low.",
author = "Hiroyuki Murai",
year = "2014",
month = "1",
day = "1",
doi = "10.5692/clinicalneurol.54.947",
language = "English",
volume = "54",
pages = "947--949",
journal = "Clinical Neurology",
issn = "0009-918X",
publisher = "Societas Neurologica Japonica",
number = "12",

}

TY - JOUR

T1 - Myasthenia gravis

T2 - Past, present and future

AU - Murai, Hiroyuki

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Myasthenia gravis (MG) was first described in 17th century. It was after 1960s, when it became clear that MG was an autoimmune disease targeting AChR. Recently, anti-MuSK and anti-Lrp4 antibodies were found as novel antibodies in MG. In 1980s, in addition to cholinesterase inhibitors, high-dose corticosteroid treatment was introduced. This dramatically reduced the mortality rate of MG, but now we recognized that side effects of steroid have influenced patients significantly, and that high dose of steroid correlate with poor QOL. Since we have more means to treat MG at present, and also in the future, we should shift to the strategy in which steroid dose is kept low.

AB - Myasthenia gravis (MG) was first described in 17th century. It was after 1960s, when it became clear that MG was an autoimmune disease targeting AChR. Recently, anti-MuSK and anti-Lrp4 antibodies were found as novel antibodies in MG. In 1980s, in addition to cholinesterase inhibitors, high-dose corticosteroid treatment was introduced. This dramatically reduced the mortality rate of MG, but now we recognized that side effects of steroid have influenced patients significantly, and that high dose of steroid correlate with poor QOL. Since we have more means to treat MG at present, and also in the future, we should shift to the strategy in which steroid dose is kept low.

UR - http://www.scopus.com/inward/record.url?scp=84919763995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919763995&partnerID=8YFLogxK

U2 - 10.5692/clinicalneurol.54.947

DO - 10.5692/clinicalneurol.54.947

M3 - Article

C2 - 25672677

AN - SCOPUS:84919763995

VL - 54

SP - 947

EP - 949

JO - Clinical Neurology

JF - Clinical Neurology

SN - 0009-918X

IS - 12

ER -